SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Monkey pox vesicles in a hand
Policy
Bavarian Nordic Seeks Help as Monkeypox Vaccine Supply Line Crumbles
Cases of monkeypox are growing at an alarming rate and Bavarian Nordic, the company that owns one of the two approved vaccines, may no longer be able to keep up.
August 18, 2022
 · 
2 min read
 · 
Tristan Manalac
Policy
In Historic Ruling, FDA Allows Sale of Over-the-Counter Hearing Aids
The FDA expects to foster innovation and competition among manufacturers, which would lower the prices of hearing aids without compromising their quality.
August 17, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of nitpicker/Getty Images
Drug Development
Phase III Flop Ends Sanofi’s SERD Breast Cancer Candidate
All other ongoing and pending studies of Sanofi’s amcenestrant, including the early-stage breast cancer trial AMEERA-6, will also be discontinued.
August 17, 2022
 · 
3 min read
 · 
Tristan Manalac
Sarah Silbiger/Getty Images
Policy
FDA Clock Starts for AstraZeneca and Merck in Prostate Cancer, Roche in DLBCL
The FDA has accepted the sNDA for AstraZeneca and Merck’s Lynparza and the sBLA for Genentech (Roche)'s for Polivy in diffuse large B-cell lymphoma.
August 16, 2022
 · 
3 min read
 · 
Tristan Manalac
Courtesy Taljat David/Getty Images
Drug Development
Novartis’ Canakinumab Flunks Another Phase III NSCLC Trial
Novartis released results from the Phase III CANOPY-A trial, showing that its canakinumab candidate failed to meet its primary efficacy endpoint in adult NSCLC patients.
August 15, 2022
 · 
3 min read
 · 
Tristan Manalac
Study: Implantable Corneas from Pig Skin Restore Vision to Blind
In a small pilot study, the implants were able to restore corneal thickness and curvature to normal levels, and vision outcomes were as good as if human-donated corneas had been used.
August 12, 2022
 · 
2 min read
 · 
Tristan Manalac
Terazosin shows top line results in ALS treatment.
FDA-Approved Hypertension Drug Shows Promise in ALS
Scientists from the University of Edinburgh have shown that Terazosin approved for high blood pressure and prostate enlargement could be repurposed for another unlikely indication: ALS.
August 12, 2022
 · 
3 min read
 · 
Tristan Manalac
Pictured: Stop sign in front of FDA headquarters/S
Drug Development
FDA Wants More Answers Before Releasing Clinical Hold on MaaT’s GvHD Drug MaaT013
MaaT Pharma announced that the U.S. FDA has maintained the clinical hold on MaaT013, its candidate for patients with steroid-resistant acute graft-versus-host disease.
August 11, 2022
 · 
2 min read
 · 
Tristan Manalac
Katherine Welles
Policy
Merck’s Blockbuster Diabetes Drug Sitagliptin Found Contaminated with Potential Carcinogen
The FDA will still allow continued distribution of sitagliptin containing NTTP with an acceptable intake limit of 37 ng per day and up to 246.7 ng per day.
August 10, 2022
 · 
3 min read
 · 
Tristan Manalac
MIT Makes Possible Breakthrough in Enabling Implantable Insulin Device
If established as safe and effective in humans, this technology could prove transformative in treating many diseases, such as diabetes.
August 10, 2022
 · 
3 min read
 · 
Tristan Manalac
Pictured: Novavax/Getty Images, STR/NurPhoto
Business
Novavax Hit Hard by Late Vaccine, while BioNTech Touts Variant-Adapted Shots
Novavax released its second quarter financial results, showing a dramatic adjustment in its sales outlook, while BioNTech prepares to launch two variant-adopted bivalent shots.
August 9, 2022
 · 
3 min read
 · 
Tristan Manalac
Leon Neal/Getty Images
Business
GSK Ups Ante in ADC Discovery Game with $1.4B Mersana Option Deal
Mersana unveiled a global collaboration with GSK, which gives GSK the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate XMT-2056.
August 9, 2022
 · 
3 min read
 · 
Tristan Manalac
KarXT can be the new hope for schizophrenia patien
Drug Development
Karuna’s KarXT Drug Could Signal New Hope for Schizophrenia - Updated
Karuna Therapeutics released results from the Phase III EMERGENT-2 trial showing that KarXT, its lead candidate, can strongly reduce symptom severity in schizophrenia patients.
August 8, 2022
 · 
3 min read
 · 
Tristan Manalac
A Question of Life and Death: Yale Scientists Bring Pig Organs Back to Life
If replicated in humans, this technology could prolong organ health during major surgeries and improve the availability of donor organs.
August 8, 2022
 · 
3 min read
 · 
Tristan Manalac
Michel Stoupak/NurPhoto via Getty Images
Business
Sanofi Expands China Footprint with Innovent Collaboration
The agreement will grant Innovent exclusive development and marketing rights to tusamitamab in China, while Sanofi will be entitled to up to $81 million in milestones and royalties.
August 5, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More